Clinical Observation Of Bushen Qiangdu Tongluo Prescribe On Ankylosing Spondylitis Of Liver Kidney Deficiency Type And Its Effect On Serum TNF-α And IL-17

Objective: To observe the clinical efficacy of Bushen Qiang Du Tongluo Prescribe in the treatment of ankylosing spondylitis with deficiency of liver and kidney and its effect on serum TNF-α and IL-17,and to evaluate its clinical safety.Methods: A total of 60 patients with ankylosing spondylitis of liver and kidney deficiency type who were admitted to the Department of Rheumatology of Henan Hospital of Traditional Chinese Medicine from December 2019 to December 2020 were collected and numbered according to their order of visit.SPSS 21.0 statistical software was used to completely randomly divide the two groups into two groups: 30 patients in the experimental group and 30 patients in the control group.The control group was treated with salazosulfadiazine and celecoxib orally,and the experimental group was additively treated with Bushi Qiangdu Tongluo prescription on the basis of the control group.Both groups were treated continuously for 8 weeks.The changes of TCM syndrome score,VAS score,AS disease activity index(BASDAI),AS functional index(BASFI),ESR,CRP,serum TNF-α and IL-17 levels in 2 groups before and after treatment were observed,and the data were statistically analyzed.Results:(1)Therapeutic effect of TCM syndromes: After treatment,the effective rate of TCM syndromes in the experimental group was 86.67%,while that in the control group was 72.41%.The experimental group was better than the control group(P<0.05),and the difference was statistically significant.(2)TCM syndrome score: After treatment,the TCM syndrome score of both groups decreased(P<0.05).Through the comparison between groups,the experimental group was better than the control group(P<0.05),the difference was statistically significant.(3)VAS score: After treatment,the VAS score of both groups was reduced(P<0.05).By comparison between groups,the experimental group was better than the control group in reducing the VAS score(P<0.05),and the difference was statistically significant.(4)BASDAI and BASFI: After treatment,the scores of BASDAI and BASFI in the two groups decreased(P<0.05).Through comparison between groups,the experimental group was better than the control group in improving BASDAI and BASFI(P<0.05),and the difference was statistically significant.(5)Laboratory indicators: after treatment,the levels of ESR and CRP in both groups decreased(P<0.05),and the experimental group was better than the control group(P < 0.05)by comparison between groups,the difference was statistically significant.(6)Cytocytokines: After treatment,the expression levels of TNF-α and IL-17 in both groups were decreased compared with before treatment(P<0.05).By comparison between groups,the expression of cytokines in the experimental group was better than that in the control group(P<0.05),and the difference was statistically significant.(7)Safety analysis: there was 1 case of ADR in the experiment al group and 2cases in the control group,and there was no statistically significant difference between the two groups(P>0.05).Conclusions: 1.Bushen Qiangdu Tongluo Decoction combined with western medicine can effectively relieve the clinical symptoms of patients with liver and kidney deficiency-type ankylosing spondylitis,reduce VAS scores,and improve BASDAI and BASFI;2.Bushen Qiangdu Tongluo Decoction combined with Western medicine can be used to treat ankylosing spondylitis.Effectively reduce th e patient’s ESR and CRP levels,inhibit the expression of TNF-α and IL-17 in the patient’s serum,thereby inhibiting inflammation and controlling the disease.